Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy

Drug Resistance Updates(2024)10.1016/j.drup.2024.101085Source: DataRank Database

Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy is a research paper published in Drug Resistance Updates (2024). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 3.74)OA: greenTopics (35)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Xinyi Tu ORCID,Xiaonan Hou,Jia Yu,Fei Zhao ORCID,Jinzhou Huang ORCID

Live enrichment

PubMed:38636338 PMC:PMC11095636 OpenAlex:https://openalex.org/W4394858256

Mayo Clinic

Grant: HD065987

Mayo Clinic

Grant: P50 CA116201

Mayo Clinic

Grant: P30 CA015083

Mayo Clinic

Grant: P50 CA136393

Mayo Foundation for Medical Education and Research

Grant: R01 CA264600

NIGMS NIH HHS

Grant: T32 GM145408

NICHD NIH HHS

Grant: K12 HD065987

American Society for Radiation Oncology

NICHD

FWCI

3.74

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11095636/pdf/nihms-1989146.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1368764624000438?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1368764624000438?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11095636

Fields of Study

PARP inhibition in cancer therapyDNA Repair MechanismsImmune Cell Function and Interaction

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsSyk KinaseAnimalsDNA DamageDNA RepairFemaleHumansOvarian NeoplasmsPhosphorylationDrug Resistance, NeoplasmCell Line, TumorDNA Breaks, Double-StrandedHomologous RecombinationAtaxia Telangiectasia Mutated ProteinsTriple Negative Breast Neoplasms

Keywords

SykCancer researchOlaparibHomologous recombinationDNA repairDNA damageBiologyPoly ADP ribose polymeraseDNATyrosine kinaseCell biologyPolymeraseSignal transductionGeneticsCancer ResistanceCtipDna Targeted Therapy

Sustainable Development Goals

SDG 0: Good health and well-being